Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $86.52, for a total value of $133,327.32. Following the sale, the insider now directly owns 1,541 shares of the company’s stock, valued at $133,327.32. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Naarden Jacob Van also recently made the following trade(s):

  • On Monday, September 18th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $89.20, for a total value of $137,457.20.
  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $89.00, for a total value of $274,298.00.
  • On Monday, August 14th, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $73.73, for a total value of $113,617.93.
  • On Tuesday, August 15th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $73.57, for a total value of $226,742.74.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same period last year, the firm posted ($0.77) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Loxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 Shares” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/01/loxo-oncology-inc-loxo-insider-naarden-jacob-van-sells-1541-shares.html.

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $94.00 target price (up from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research lowered Loxo Oncology from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Ifs Securities reissued an “outperform” rating on shares of Loxo Oncology in a report on Tuesday, August 8th. Finally, BTIG Research reissued a “buy” rating and issued a $102.00 price objective (up previously from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $80.02.

Several large investors have recently added to or reduced their stakes in LOXO. FMR LLC grew its holdings in Loxo Oncology by 12.1% during the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after buying an additional 472,814 shares in the last quarter. BlackRock Inc. grew its holdings in Loxo Oncology by 20.6% during the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after buying an additional 273,291 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Loxo Oncology by 50.2% during the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after buying an additional 312,988 shares in the last quarter. Vanguard Group Inc. grew its holdings in Loxo Oncology by 24.7% during the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after buying an additional 181,471 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in Loxo Oncology by 372.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after buying an additional 582,862 shares in the last quarter.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.